Drug Search Results
More Filters [+]

AdCOVID

Alternative Names: AdCOVID
Latest Update: 2023-08-16
Latest Update Note: PubMed Publication

Product Description

AdCOVID, an intranasal adenovirus type 5 (Ad5)-vectored vaccine encoding the receptor binding domain (RBD) of the SARS-CoV-2 spike protein, elicits a strong and focused immune response against RBD through the induction of mucosal IgA, serum neutralizing antibodies and CD4+ and CD8+ T cells with a Th1-like cytokine expression profile. Therefore, AdCOVID, which promotes concomitant systemic and local mucosal immunity, represents a promising COVID-19 vaccine candidate. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553185/)

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Altimmune
Company Location: GAITHERSBURG MD 20878
Company CEO: Vipin K. Garg
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AdCOVID

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: COVID-19

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

COVID-19 Vaccine Study

P1

Completed

COVID-19

2021-12-01

22%

Recent News Events